FLT3-ITD signals bad news for core binding factor acute myeloid leukemia unless trisomy 22 comes to the rescue

por Loo, Sun, Wei, Andrew H.
Publicado 2021

BCL2 Inhibition: A New Paradigm for the Treatment of AML and Beyond

por Wei, Andrew H., Roberts, Andrew W.
Publicado 2023

New Drugs Bringing New Challenges to AML: A Brief Review

por Yeoh, Zhi Han, Bajel, Ashish, Wei, Andrew H.
Publicado 2021

Venetoclax联合低剂量阿糖胞苷治疗不耐受强化化疗的初治急性髓系白血病患者：一项Ⅲ期随机、安慰剂对照试验中中国队列结果

por Zha, Jiuhong, Qi, Jiang, Wu, Jun, Mendes, Wellington, Wei, Andrew H.
Publicado 2021

Dissecting causes for improved survival among patients with acute myeloid leukemia in two different eras receiving identical regimens in sequential randomized studies

por Tiong, Ing S., Reynolds, John, Bradstock, Kenneth F., Seymour, John F., Wei, Andrew H.
Publicado 2018

Clinical Significance of Transient Asymptomatic Elevations in Aminotransferase (TAEAT) in Oncology

por Lewis, James H., Khaldoyanidi, Sophia K., Britten, Carolyn D., Wei, Andrew H., Subklewe, Marion
Publicado 2022

New directions for emerging therapies in acute myeloid leukemia: the next chapter

por Daver, Naval, Wei, Andrew H., Pollyea, Daniel A., Fathi, Amir T., Vyas, Paresh, DiNardo, Courtney D.
Publicado 2020

Structural Basis for Apoptosis Inhibition by Epstein-Barr Virus BHRF1

por Kvansakul, Marc, Wei, Andrew H., Fletcher, Jamie I., Willis, Simon N., Chen, Lin, Roberts, Andrew W., Huang, David C. S., Colman, Peter M.
Publicado 2010

Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia

por Chua, Chong Chyn, Hammond, Danielle, Kent, Andrew, Tiong, Ing Soo, Konopleva, Marina Y., Pollyea, Daniel A., DiNardo, Courtney D., Wei, Andrew H.
Publicado 2022

Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia

por Wei, Andrew H., Ribera, Josep-Maria, Larson, Richard A., Ritchie, David, Ghobadi, Armin, Chen, Yuqi, Anderson, Abraham, Dos Santos, Cedric E., Franklin, Janet, Kantarjian, Hagop
Publicado 2021

TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions

por Daver, Naval G., Maiti, Abhishek, Kadia, Tapan M., Vyas, Paresh, Majeti, Ravindra, Wei, Andrew H., Garcia-Manero, Guillermo, Craddock, Charles, Sallman, David A., Kantarjian, Hagop M.
Publicado 2022

Venetoclax exposure‐efficacy and exposure‐safety relationships in patients with treatment‐naïve acute myeloid leukemia who are ineligible for intensive chemotherapy

por Brackman, Deanna, Eckert, Doerthe, Menon, Rajeev, Salem, Ahmed Hamed, Potluri, Jalaja, Smith, B. Douglas, Wei, Andrew H., Hayslip, John, Miles, Dale, Mensing, Sven, Gopalakrishnan, Sathej, Zha, Jiuhong
Publicado 2022

Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QU...

por Wei, Andrew H., Roboz, Gail J., Dombret, Hervé, Döhner, Hartmut, Schuh, Andre C., Montesinos, Pau, Selleslag, Dominik, Bondarenko, Sergey N., Prebet, Thomas, Lai, Yinzhi, Skikne, Barry, Beach, C.L., Ravandi, Farhad
Publicado 2023

Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine

por Pollyea, Daniel A., Pratz, Keith W., Wei, Andrew H., Pullarkat, Vinod, Jonas, Brian A., Recher, Christian, Babu, Sunil, Schuh, Andre C., Dail, Monique, Sun, Yan, Potluri, Jalaja, Chyla, Brenda, DiNardo, Courtney D.
Publicado 2022

Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia

por Konopleva, Marina, Thirman, Michael J., Pratz, Keith W., Garcia, Jacqueline S., Recher, Christian, Pullarkat, Vinod, Kantarjian, Hagop M., DiNardo, Courtney D., Dail, Monique, Duan, Yinghui, Chyla, Brenda, Potluri, Jalaja, Miller, Catherine L., Wei, Andrew H.
Publicado 2022

Outcomes following venetoclax‐based treatment in therapy‐related myeloid neoplasms

por Shah, Mithun Vinod, Chhetri, Rakchha, Dholakia, Ruchita, Kok, Chung H., Gangat, Naseema, Alkhateeb, Hassan B., Al‐Kali, Aref, Patnaik, Mrinal M., Baranwal, Anmol, Greipp, Patricia T., He, Rong, Begna, Kebede H., Tiong, Ing Soo, Wei, Andrew H., Hiwase, Devendra
Publicado 2022

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine

por Döhner, Hartmut, Wei, Andrew H., Roboz, Gail J., Montesinos, Pau, Thol, Felicitas R., Ravandi, Farhad, Dombret, Hervé, Porkka, Kimmo, Sandhu, Irwindeep, Skikne, Barry, See, Wendy L., Ugidos, Manuel, Risueño, Alberto, Chan, Esther T., Thakurta, Anjan, Beach, C.L., Lopes de Menezes, Daniel
Publicado 2022

Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low‐intensity chemotherapy in acute myeloid leukaemia

por Tiong, Ing S., Dillon, Richard, Ivey, Adam, Teh, Tse‐Chieh, Nguyen, Phillip, Cummings, Nicholas, Taussig, David C., Latif, Annie‐Louise, Potter, Nicola E., Runglall, Manohursingh, Russell, Nigel H., Raj, Kavita, Schwarer, Anthony P., Fong, Chun Yew, Grigg, Andrew P., Wei, Andrew H.
Publicado 2020

Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia

por Jonas, Brian A., Wei, Andrew H., Recher, Christian, DiNardo, Courtney D., Jang, Jun‐Ho, Pratz, Keith, Panayiotidis, Panayiotis, Montesinos, Pau, Yeh, Su‐Peng, Ivanov, Vladimir, Fiedler, Walter, Yamauchi, Takahiro, Duan, Yinghui, Mendes, Wellington, Potluri, Jalaja, Tews, Björn, Ofran, Yishai
Publicado 2022

Protein Kinase Activity of Phosphoinositide 3-Kinase Regulates Cytokine-Dependent Cell Survival

por Thomas, Daniel, Powell, Jason A., Green, Benjamin D., Barry, Emma F., Ma, Yuefang, Woodcock, Joanna, Fitter, Stephen, Zannettino, Andrew C. W., Pitson, Stuart M., Hughes, Timothy P., Lopez, Angel F., Shepherd, Peter R., Wei, Andrew H., Ekert, Paul G., Guthridge, Mark A.
Publicado 2013